An FDA advisory committee voted in favor of supporting a respiratory syncytial virus therapy designed to protect newborns and infants. The antibody drug developed by partners Sanofi and AstraZeneca is currently under regulatory review.
Sanofi, AstraZeneca RSV Drug for Infants Secures Backing of FDA Advisors
